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Background
A small, but significant number of subcutaneous immu-
notherapy (SCIT) based systemic reactions (SR) result in
morbidity and mortality. SR range from 4 to 7% for tradi-
tional protocols and up to 34% if undergoing RUSH immu-
notherapy. There is estimated 1 death per 2.5 million
immunotherapy injections. We report the results of an IRB
approved study and contrast the safety of the United
Allergy Services (UAS) SCIT treatment protocol to pre-
viously published reports. We hypothesized that a slower
SCIT build up phase and pre-selection for low risk patients
would prove to be safer than traditional protocols.
Methods
A slow incremental SCIT build up phase (6 months vs.
3 months to achieve maintenance) and careful exclusion
of high risk patients were salient features of the SCIT pro-
tocol utilized for 18,971 adults who were administered
1,624,135 injections and 4,643 pediatric patients (< 18 y/o)
who were administered 397,466 SCIT injections for a
1 year period (2011-2012).
Results
The adult patient SR rate per patient was 0.15% and
0.002% per injection. The pediatric patient SR rate per
patient was 0.19% and per injection was 0.002%. SR rate
assessment for the entire patient population was 0.16%
per patient and 0.002%per injection. These results are in
contrast to a reported 4% SR rate for 773 adult patients
who were administered 28,000 injections (Allergy
Asthma Proc. 2011;32(4):288) and up to 4.6% per injec-
tion reported for pediatric patients (Pediatrics 2013:131,
1155). The remarkably low UAS SR rates are signifi-
cantly below (p < 0.0001) the cited published results.
The SR for all patients are: Anaphylaxis Grade I-18,
Grade II-17, Grade III-1, Grade IV-1; and for pediatric
patients: Grade I-5 & Grade II- 4. Of note, no Grade V
reactions (deaths) occurred in over 2 million injections.
Conclusions
These results demonstrate the safety of the UAS immu-
notherapy protocol. We conclude that the UAS SCIT pro-
tocol is safe with minimal SR in comparison to previously
published protocols. These safety results are due to a
slower incremental SCIT build up phase and a pre-selec-
tion of low risk patients.
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